# Nuclide record pheochromocytoma-paraganglioma (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/pheochromocytoma-paraganglioma/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "pheochromocytoma-paraganglioma" ;
  schema:name "Pheochromocytoma and paraganglioma (PPGL)"@en ;
  schema:alternateName "Pheochromocytoma"@en, "Paraganglioma"@en, "PPGL"@en, "Phaeochromocytoma"@en ;
  schema:description "Pheochromocytomas and paragangliomas are tumours of adrenaline-producing tissue that cause dangerous blood pressure surges. Surgery after careful blood-pressure blockade cures most, genetic testing finds an inherited cause in nearly half, and for the minority that spread there are now radioactive drugs that home to the tumour and, since 2025, the first oral targeted pill, belzutifan."@en ;
  schema:url <https://nuclide.cc/indications/pheochromocytoma-paraganglioma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pheochromocytoma> ;
  schema:citation <https://www.cancer.gov/types/pheochromocytoma>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma>, <https://doi.org/10.1210/jc.2014-1498>, <https://doi.org/10.1016/S0140-6736(23)02554-0> ;
  nuclide:tag "nci-coverage", "rare", "endocrine" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/i-131/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/mibg-theranostics/>, <https://nuclide.cc/technologies/sstr-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/i131-mibg/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/temozolomide/>, <https://nuclide.cc/drugs/cabozantinib/> ;
  nuclide:companies <https://nuclide.cc/companies/merck/>, <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/pfizer/> ;
  nuclide:pathways <https://nuclide.cc/pathways/hif-vhl/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/cabozantinib/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/drugs/i131-mibg/>, <https://nuclide.cc/technologies/mibg-theranostics/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/temozolomide/> .